Prognostic Value of Cerebrospinal Fluid Immunoglobulin Free Light Chains in Patients With Multiple Sclerosis

NCT05072691 | Recruiting

• 1 other identifier: CHUB-Neuro-Lab-MS
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system, usually presenting as clinically isolated syndrome (CIS). The course of MS following first symptoms is unpredictable, as approximately 30% of patients with MS have a benign course and don't develop significant disability while another 20-30% progress to severe disability within a relatively short time period. In this context, it is difficult to counsel an individual patient and choose the best treatment option at time of diagnosis. For these reasons, prognostic markers that could be used to predict future disease course are extremely useful. The only cerebrospinal fluid (CSF) prognostic biomarker currently used in clinical practice are oligoclonal bands (OCB) that can predict conversion from CIS to clinically definite MS, although this observation is not consistent. However, OCB analyses are qualitative with issues in reproducibility and a limited dynamic range. CSF immunoglobulin (Ig) free light chains (FLC) are a quantitative measure of humoral response in CSF that has showed greater sensitivity and specificity than OCB for confirming diagnosis of MS. Moreover, in few recent studies they seem to have also a prognostic value, predicting conversion from CIS to clinically definite MS and correlating with the Expanded Disability Status Scale (EDSS). Optic Neuritis (ON) can be a first clinical relapse of MS and is particularly interesting because it may constitute a suitable clinical model for neuroprotection studies, as visual function can be measured with quantitative methods, including Visual Evoked Potential (VEP) and Optical Coherence Tomography (OCT). The investigators aim to better explore the utility of CSF Ig FLC as potential prognostic biomarker for MS, and to predict the recovery of visual function after ON, as model of MS relapse. The investigators will study its potential correlation with MS relapses, with changes in several functional outcome scores, exploring physical disability, fatigue, behavior, cognition, upper and lower extremity function, and with MRI disease activity. For a subgroup of patient, the investigators aim to explore its potential correlation with in vivo measures of demyelination and neuronal and axonal loss after ON, as model of potential recovery after MS relapse. The investigators aim also to compare the prognostic value of Ig FLC with Neurofilament light chain (NfL), a potential prognostic biomarker wider studied in MS.

Conditions

Multiple Sclerosis

Outcome Measures

Primary Outcomes (18)

• Expanded Disability Status Scale (EDSS)

  Ordinal scale of 0.0-10 ("no disability" to "death due to MS"), with higher scores reflecting greater level of disability.

  Change from baseline (time of enrollment) up to 4 years

• Fatigue Severity Scale (FSS)

  Frequently used nine-item questionnaire for the evaluation of fatigue in patients with MS (10). The FSS score is the mean score of the nine items with a cut-off for fatigue set to ≥ 4.

  Change from baseline (time of enrollment) up to 4 years

• Hospital Anxiety and Depression Scale (HADS)

  The scale is a 14-item self-report measure with seven items each in the depression and anxiety subscales. Each item was scored on a scale of 0-3, with a total potential score of 21, where a threshold score of 8 or greater on each subscale is considered indicative of clinically significant anxiety or depression.

  Change from baseline (time of enrollment) up to 4 years

• Symbol-Digit Modalities Test (SDMT)

  The test consists of a series of single digits paired with nine symbols, as a reference key. The patient views a pseudorandomized sequence of these symbols and orally responds with the matching digit. The final score is the number of correct responses within 90 seconds, with higher scores corresponding to faster processing speed.

  Change from baseline (time of enrollment) up to 4 years

• Nine Hole Peg Test (NHPT)

  Brief, standardized, quantitative test, where the patient picks up nine pegs one at a time as quickly as possible, puts them in nine holes, and, once they are in the holes, removes them again as quickly as possible one at a time, replacing them into a container. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The final score is an average of the four trials.

  Change from baseline (time of enrollment) up to 4 years

• Timed 25-Foot Walk (T25FW)

  Quantitative mobility and leg function performance test where the patient is instructed to walk 25 feet as quickly as possible. The time is calculated from the initiation of the instruction to start and ends when the patient has reached the 25-foot mark. The task is immediately administered again by having the patient walk back the same distance. The score is the average of time for the two completed trials.

  Change from baseline (time of enrollment) up to 4 years

• Six Spot Step Test (SSST)

  The patient is instructed to walk as quickly as possible from one end to the other of a rectangular field measuring 1 x 5 m, while kicking five cylinder blocks out of five circles marked on the floor. The patient has to do four runs, two for each leg. The total score of the SSST is the mean value of time used for each of the four runs.

  Change from baseline (time of enrollment) up to 4 years

• Ambulation Score (AS)

  The AS is the measure of the distance the patient is able to walk in meters. The score ranges from 0 (ambulation unrestricted) to 12 (essentially restricted to bed).

  Change from baseline (time of enrollment) up to 4 years

• Annualized relapse rate (ARR)

  Number of relapses per year from disease onset

  Once a year during the observational period.

• MRI data: T2 lesions

  T2 lesion load in brain and spinal cord

  Change from baseline (time of enrollment) up to 4 years

• MRI data : gadolinium enhancing lesions

  Gadolinium enhancing lesions in brain and spinal cord

  Change from baseline (time of enrollment) up to 4 years

• P100 latency (VEP)

  VEP is a measurement of the electrical signal recorded at the scalp over the occipital cortex in response to light stimulus. The studied VEP contains an initial negative peak (N1), followed by a positive peak (P100). Demyelination of the optic nerve results in increased latency of the P100 waveform, without significant effect on amplitude.

  Change from baseline (time of enrollment) up to 4 years

• Visual acuity

  Low-contrast letter acuity chart measured by low-contrast Sloan letter chart.

  Change from baseline (time of enrollment) up to 4 years

• Visual field

  Visual field measured by 30-2 SITA Standard visual field test

  Change from baseline (time of enrollment) up to 4 years

• Color discrimination

  Color discrimination measured by Ishihara test

  Change from baseline (time of enrollment) up to 4 years

• GCL thickness (OCT)

  OCT is a technique using light waves to take cross-section pictures of retina. It allows measuring of thickness of different retinal layer. The anterior visual pathways consist of the retinal ganglion cells, whose somas are in the ganglion cell layer (GCL) and axons form the retinal nerve fiber layer (RNFL). Assessment of the RNFL and GCL using OCT potentially allows assessing of axonal and neuronal degeneration.

  Change from baseline (time of enrollment) up to 4 years

• RNFL thickness (OCT)

  OCT is a technique using light waves to take cross-section pictures of retina. It allows measuring of thickness of different retinal layer. The anterior visual pathways consist of the retinal ganglion cells, whose somas are in the ganglion cell layer (GCL) and axons form the retinal nerve fiber layer (RNFL). Assessment of the RNFL and GCL using OCT potentially allows assessing of axonal and neuronal degeneration.

  Change from baseline (time of enrollment) up to 4 years

• immunoglobulin (Ig) free light chains (FLC)

  Ig FLC concentrations will be measured using the Freelite Mx (CSF) assay (The Binding Site Group, Bimingham, UK) in the peripheral blood and cerebrospinal fluid.

  Baseline

Study Arms (3)

Patients with Multiple sclerosis and Optic Neuritis

Patients ≥ 18 year-old at the time of enrollment, with newly diagnosed multiple sclerosis according to 2017 McDonald diagnostic criteria Patients ≥ 18 year-old at the time of enrollment with first episode of optic neuritis, fulfilling or not (i.e. CIS, clinically isolated syndrome) 2017 McDonald diagnostic criteria for multiple sclerosis

Diagnostic Test: CSF immunoglobulin (Ig) free light chains (FLC) dosage

Patients with non-inflammatory neurologic diseases (NIND)

Patients ≥ 18 year-old with suspected non-inflammatory neurologic diseases (such as Alzheimer disease, intracranial hypertension, etc) receiving routine diagnostic lumbar puncture

Diagnostic Test: CSF immunoglobulin (Ig) free light chains (FLC) dosage

Patients with other inflammatory neurologic diseases (IND)

Patients ≥ 18 year-old with suspected inflammatory neurologic diseases other than multiple sclerosis (such as inflammatory peripheral neuropathies, meningitis, neuromyelitis optica spectrum disorders, etc) receiving routine diagnostic lumbar puncture

Diagnostic Test: CSF immunoglobulin (Ig) free light chains (FLC) dosage

Interventions

CSF immunoglobulin (Ig) free light chains (FLC) dosage DIAGNOSTIC_TEST

CSF immunoglobulin (Ig) free light chains (FLC) dosage in the peripheral blood and cerebrospinal fluid.

Patients with Multiple sclerosis and Optic Neuritis; Patients with non-inflammatory neurologic diseases (NIND); Patients with other inflammatory neurologic diseases (IND)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

* Patients with MS and ON * Patients with non-inflammatory neurologic diseases (NIND) and patients with other inflammatory neurologic diseases (IND) as control group

You may qualify if:

• Age ≥ 18 at the time of enrollment
• Diagnosis of multiple sclerosis according to 2017 McDonald diagnostic criteria or optic neuritis (fulfilling or not criteria for multiple sclerosis, i.e. clinically isolated syndrome)
• Receiving both lumbar puncture and brain MRI for the routine diagnostic work-up

You may not qualify if:

• None

Sponsors & Collaborators

• Francis Corazza: lead

Study Sites (1)

CHU Brugmann

Brussels, 1020, Belgium

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

peripheral blood and cerebrospinal fluid

MeSH Terms

Conditions

Multiple Sclerosis

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Demyelinating Diseases; Autoimmune Diseases; Immune System Diseases

Study Officials

• Serena Borrelli

  CHU Brugmann

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Serena Borrelli, MD

CONTACT

3224750308; Serena.BORRELLI@chu-brugmann.be

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Head of Immunology laboratory

Study Record Dates

• First Submitted: September 13, 2021
• First Posted: October 11, 2021
• Study Start: July 14, 2020
• Primary Completion (Estimated): January 1, 2030
• Study Completion (Estimated): January 1, 2030
• Last Updated: October 6, 2025

Record last verified: 2025-10

Data Sharing

• IPD Sharing: Will not share

Locations

BE (1)